NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Forecast, Price & News

$7.55

-0.05 (-0.66%)

(As of 09/25/2023 ET)

Compare

Today's Range: $7.40
▼
$7.60
50-Day Range: $7.55
▼
$10.23
52-Week Range: $4.77
▼
$14.34

Volume: 221,866 shs
Average Volume: 459,213 shs
Market Capitalization: $331.45 million

P/E Ratio: 3.33
Dividend Yield: N/A
Price Target: $17.00

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 125.2% Upside
$17.00 Price Target
Short Interest: Bearish
5.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: -0.14
Based on 18 Articles This Week
Insider Trading: Selling Shares
$145,080 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From $1.11 to ($1.59) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

433rd out of 961 stocks

Biological Products, Except Diagnostic Industry

68th out of 161 stocks

3.3

Analyst's Opinion

Consensus Rating
Voyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Voyager Therapeutics has a forecasted upside of 125.2% from its current price of $7.55.
Amount of Analyst Coverage
Voyager Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.98% of the float of Voyager Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Voyager Therapeutics has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Voyager Therapeutics has recently increased by 2.46%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Voyager Therapeutics does not currently pay a dividend.
Dividend Growth
Voyager Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Voyager Therapeutics has received a 77.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Voyager Therapeutics is -0.62.

1.6

News and Social Media Coverage

News Sentiment
Voyager Therapeutics has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for Voyager Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
69 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 6,800% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $145,080.00 in company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Voyager Therapeutics is held by insiders.
Percentage Held by Institutions
58.81% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Voyager Therapeutics are expected to decrease in the coming year, from $1.11 to ($1.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Voyager Therapeutics is 3.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.23.
Price to Earnings Ratio vs. Sector
The P/E ratio of Voyager Therapeutics is 3.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.18.
Price to Book Value per Share Ratio
Voyager Therapeutics has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

VYGR Price History

30 days | 90 days | 365 days | Advanced Chart

VYGR Stock News Headlines

September 25, 2023 | msn.com

Corsair's Voyager gaming laptop is now $1,200 off

September 25, 2023 | finance.yahoo.com

Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

September 25, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 24, 2023 | msn.com

Assessing Voyager's Alzheimer's Treatment Potential

September 22, 2023 | msn.com

Corsair’s Voyager a1600 Gaming Laptop comes with a Ryzen R7 chip and 48 percent savings

September 22, 2023 | msn.com

Voyager's lead singer Danny Estrin reveals cancer diagnosis and cancels European tour

September 21, 2023 | msn.com

Voyager Lead Singer Danny Estrin Diagnosed with Cancer

September 21, 2023 | au.lifestyle.yahoo.com

Voyager's Danny Estrin shares 'devastating' cancer diagnosis

September 25, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 21, 2023 | yahoo.com

Voyager postpone October European tour in wake of Danny Estrin's shock cancer diagnosis

September 21, 2023 | news.yahoo.com

Voyager’s Danny Estrin, who represented Australia in Eurovision 2023, shares ‘life-altering news’

September 21, 2023 | americanbankingnews.com

Chardan Capital Reaffirms Neutral Rating for Voyager Therapeutics (NASDAQ:VYGR)

September 21, 2023 | americanbankingnews.com

FY2024 Earnings Estimate for Voyager Therapeutics, Inc. (NASDAQ:VYGR) Issued By Chardan Capital

September 19, 2023 | msn.com

Star Trek: Fans Will Never Forgive Voyager For This Missed Opportunity

September 18, 2023 | msn.com

On this date: Voyager’s first amazing photo (of Many)

September 16, 2023 | msn.com

Historic space photo of the week: Voyager 2 spies a storm on Saturn 42 years ago

September 11, 2023 | msn.com

Blue Star’s new non-executive director is a helium market insider ready to steer Voyager towards first production

September 8, 2023 | au.investing.com

Blue Star Helium upgrades Voyager well design to further optimise recovery

September 5, 2023 | msn.com

BGSU student is honored as national Obama-Chesky Voyager Scholar

August 29, 2023 | yahoo.com

Powder Review: Moment Voyager XV Evo Binding

August 25, 2023 | forbes.com

100 New Recipients Of The Obama-Chesky Voyager Scholarship Are Announced

August 21, 2023 | yahoo.com

Voyager Announce 2024 National ‘Fearless in Love’ Tour

August 19, 2023 | finance.yahoo.com

Institutional investors own a significant stake of 43% in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

August 8, 2023 | markets.businessinsider.com

Robert W. Baird Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)

August 8, 2023 | msn.com

Oppenheimer Reiterates Voyager Therapeutics (VYGR) Outperform Recommendation

August 7, 2023 | msn.com

A 'shout" across interstellar space restores contact between Voyager 2 craft and NASA

August 7, 2023 | markets.businessinsider.com

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

See More Headlines

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Company Calendar

Last Earnings: 8/03/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VYGR
CUSIP: N/A
CIK: 1640266
Web: www.voyagertherapeutics.com
Phone: (857) 259-5340
Fax: N/A
Employees: 125
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.00
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +125.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.27
Trailing P/E Ratio: 3.33
Forward P/E Ratio: 6.80
P/E Growth: N/A
Net Income: $-46,410,000.00
Net Margins: N/A
Pretax Margin: 49.58%
Return on Equity: 69.09%
Return on Assets: 38.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.22
Quick Ratio: 6.22

Sales & Book Value

Annual Sales: $40.91 million
Price / Sales: 8.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.53 per share
Price / Book: 4.93

Miscellaneous

Outstanding Shares: 43,900,000
Free Float: 41,838,000
Market Cap: $331.45 million
Optionable: Optionable
Beta: 1.03

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Alfred W. Sandrock Jr. (Age 65)
M.D., Ph.D., Pres, CEO & Director
Comp: $825.41k

Mr. Peter P. Pfreundschuh CPA (Age 54)
Chief Financial Officer
Comp: $172.73k

Dr. Krystof Bankiewicz M.D.
Ph.D., Founder

Dr. Guangping Gao Ph.D.
Founder & Member of Scientific Advisory Board

Dr. Mark A. Kay M.D. (Age 64)
Ph.D., Founder

Dr. Phillip D. Zamore Ph.D.
Founder & Member of Scientific Advisory Board

Ms. Robin Swartz (Age 52)
Chief Operating Officer

Mr. Todd Carter Ph.D. (Age 53)
Chief Scientific Officer

Ms. Jacquelyn Fahey Sandell Esq.
J.D., Chief Legal Officer

Ms. Michelle Quinn Smith
Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VYGR Stock - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VYGR shares.
View VYGR analyst ratings or view top-rated stocks.
What is Voyager Therapeutics' stock price forecast for 2023?: 3 analysts have issued 1-year price objectives for Voyager Therapeutics' stock. Their VYGR share price forecasts range from $16.00 to $18.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 125.2% from the stock's current price.
View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts.
How have VYGR shares performed in 2023?: Voyager Therapeutics' stock was trading at $6.10 at the start of the year. Since then, VYGR shares have increased by 23.8% and is now trading at $7.55.
View the best growth stocks for 2023 here.
When is Voyager Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our VYGR earnings forecast.
How were Voyager Therapeutics' earnings last quarter?: Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.08. The business earned $4.85 million during the quarter, compared to analyst estimates of $2 million.
What ETF holds Voyager Therapeutics' stock ?: iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio.

What other stocks do shareholders of Voyager Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).
What is Voyager Therapeutics' stock symbol?: Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."
Who are Voyager Therapeutics' major shareholders?: Voyager Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.64%), Acadian Asset Management LLC (1.64%), Geode Capital Management LLC (1.34%), State Street Corp (1.24%), Marshall Wace LLP (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Alfred Sandrock, Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends.
How do I buy shares of Voyager Therapeutics?: Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Voyager Therapeutics' stock price today?: One share of VYGR stock can currently be purchased for approximately $7.55.
How much money does Voyager Therapeutics make?: Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $331.45 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.27 on an earnings per share basis.
How many employees does Voyager Therapeutics have?: The company employs 125 workers across the globe.
How can I contact Voyager Therapeutics?: Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial